AMRX: Q2 revenue and profit surged, outlook raised, and biosimilar expansion accelerates with Kashiv
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw double-digit revenue and profit growth, driven by strong performance in affordable medicines, specialty, and biosimilars. The pending Kashiv acquisition will create a fully integrated biosimilar platform, while guidance for 2026 was raised across all key metrics.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw double-digit revenue and profit growth, driven by strong performance in affordable medicines, specialty, and biosimilars. The pending Kashiv acquisition will create a fully integrated biosimilar platform, while guidance for 2026 was raised across all key metrics.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.